表紙
市場調査レポート

世界の胃腸疾患治療薬市場:過敏性大腸症候群(IBS)や慢性便秘(CC)、潰瘍性大腸炎(UC)を標的とした新規薬剤による市場の活性化

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

発行 GBI Research 商品コード 253373
出版日 ページ情報 英文 171 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
世界の胃腸疾患治療薬市場:過敏性大腸症候群(IBS)や慢性便秘(CC)、潰瘍性大腸炎(UC)を標的とした新規薬剤による市場の活性化 Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market
出版日: 2012年11月01日 ページ情報: 英文 171 Pages
概要

世界の胃腸疾患治療薬の市場では、特に過敏性大腸症候群(IBS)やクローン病、潰瘍性大腸炎(UC)、胃食道逆流性疾患(GERD)、消化性潰瘍(PUC)の分野で、人気の高かった医薬品のジェネリック版が市場に次々と投入されています。一方で、より高い効能を持つ新薬の研究開発・市場投入も着々と進められており、全体としてはジェネリック医薬品による市場縮小を補って、市場規模を安定化させています。また、生活上のストレスの増加や不健康な食習慣、高齢化の進展、社会的な認知度の増大などが、市場の成長を促しています。

当レポートでは、全世界の胃腸疾患治療法の市場について分析し、世界全体および主要国の市場構造と動向(過去・今後7年間の実績値と予測値)、主な適応症別の市場の詳細(疾患概要、市場規模、年間治療費、治療法の利用パターン、市場促進・抑制要因など)、開発中のパイプライン製品の情報、主要企業の市場シェアと概要、主な資本取引の動向(年度別・地域別・金額別の件数内訳と最新動向)などを調査・推計して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の特徴

  • 市場の予測
    • ブランド薬/ジェネリック医薬品の世界市場シェア
    • 年間治療費
    • 治療法の利用パターン
  • 市場促進・抑制要因

第4章 各地域の市場環境

  • 地域別の市場収益の分析
  • 米国(市場収益・年間治療費・利用パターン)
  • 欧州主要5カ国(市場収益・年間治療費・利用パターン)
  • 日本(市場収益・年間治療費・利用パターン)
  • インド(疫学、治験、促進・抑制要因)
  • オーストラリア(疫学、治験、促進・抑制要因)
  • 中国(疫学、治験、促進・抑制要因)

第5章 治療環境

  • 過敏性大腸症候群(IBS)治療薬:世界市場の予測
  • 過敏性大腸症候群(IBS)治療薬:市場促進・抑制要因
  • 便秘治療薬:世界市場の予測
  • 便秘治療薬:市場促進・抑制要因
  • クローン病治療薬:世界市場の予測
  • クローン病治療薬:市場促進・抑制要因
  • 潰瘍性大腸炎治療薬:世界市場の予測
  • 潰瘍性大腸炎治療薬:市場促進・抑制要因
  • 胃食道逆流性疾患(GERD)治療薬:世界市場の予測
  • 胃食道逆流性疾患(GERD)治療薬:市場促進・抑制要因
  • 消化性潰瘍治療薬:世界市場の予測
  • 消化性潰瘍治療薬:市場促進・抑制要因

第6章 パイプライン分析

  • サマリー
  • 研究開発パイプライン:フェーズ別
  • 研究開発パイプライン:適応症別
  • 過敏性大腸症候群(IBS):研究開発パイプライン
  • 便秘:研究開発パイプライン:研究開発パイプライン
  • クローン病:研究開発パイプライン
  • 潰瘍性大腸炎:研究開発パイプライン
  • 胃食道逆流性疾患(GERD):研究開発パイプライン
  • 消化性潰瘍治療薬:研究開発パイプライン
  • 有望なパイプライン分子
    • Linzess (linaclotide)
    • Xifaxan (rifaximin)
    • Relistor (methylnaltrexone)
    • Humira (adalimumab)
    • Uceris (budesonide)
    • Plecanatide
    • Vedolizumab (MLN0002)
    • Naloxegol (NKTR-118)
    • Simponi (golimumab)
    • Asimadoline
    • Traficet-EN (GSK-1605786)
    • Cobiprostone

第7章 競争環境

  • 市場シェア分析
  • 主要企業のプロファイル
    • AstraZeneca
    • 武田薬品工業
    • Johnson & Johnson
    • エーザイ
    • Abbott Laboratories
    • Shire
    • Salix Pharmaceuticals

第8章 戦略的な企業統合

  • 概要
  • 企業合併・買収(M&A)
    • 主な企業合併・買収(M&A)案件
    • 年度別の件数
    • 地域別の件数
    • 金額帯別の件数
  • ライセンス契約
    • 主なライセンス契約案件
    • 年度別の件数
    • 地域別の件数
    • 金額帯別の件数
  • 共同開発/共同販売取引
    • 主な共同開発/共同販売取引
    • 年度別の件数
    • 地域別の件数
    • 金額帯別の件数

9章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC241MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market", which provides insights into the gastrointestinal disorders therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. It provides in-depth analysis of the major diseases, comprising IBS, constipation, Crohn's disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). The report also gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

GBI Research's analysis shows that the gastrointestinal disorders therapeutics market is set to witness high generic competition in the forecast period, as major drugs used in the treatment of the aforementioned disorders are set to expire, resulting in declining revenues and allowing generics to enter the market. Nevertheless, the market will witness steady growth due to the anticipated entry of innovative new drugs in the near future. Furthermore, strong R&D in IBS, constipation, Crohn's disease and UC remains a key market driver.

Scope

  • Data and analysis for the gastrointestinal disorders therapeutics markets in the leading geographies: the US; the top five countries of Europe, comprising the UK, Germany, France, Italy and Spain; Japan; and an overview of India, China and Australia
  • Annualized market data for the gastrointestinal disorders therapeutics market from 2004 to 2010 and forecast to 2018
  • Market data for the geographical and therapeutic landscapes, including size, share, annual cost of therapy, sales volume and treatment usage patterns for the diseased population, diagnosis population and prescription population
  • Generic share in the global market and for each indication
  • Key drivers and restraints that have had a significant impact on the market
  • The competitive landscape of the global market, looking at key companies such as AstraZeneca, Takeda, Johnson & Johnson , Eisai, Abbott, Shire and Salix
  • Key M&A activity and licensing agreements that took place between 2010 and 2012

Reasons to buy

  • Align product portfolios to the markets with high growth potential
  • Build effective strategies to launch pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
  • Develop key strategic initiatives by studying top competitors' key strategies
  • Device a more tailored country strategy by understanding the key drivers, barriers and market potential for each indication
  • Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms producing safer and more efficacious FIC molecules

Executive Summary

Researchers Bust a Gut to Improve Gastrointestinal Disorders Market

Drugs to treat gastrointestinal disorders are due to see a significant price drop, as patents run out and research takes off, according to a new report by healthcare experts GBI Research.

The new report* states that patients with disorders such as Irritable Bowel Syndrome (IBS), Crohn's disease, Ulcerative Colitis (UC), Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD) will experience a rush in new generic versions of popular medication, and new novel drugs with the hope of better results.

The market for gastrointestinal disorder therapeutics is being driven by increased stress, unhealthy eating habits, the growth of the global elderly population and an increased level of awareness among the general population, which has spurred on the rise of incidence and diagnosis over the recent past. Anxiety, unhealthy foods and advanced age can all be associated with changes in gastrointestinal physiology. However, gastrointestinal diseases still have a low diagnosis rate, and a fear of serious side effects may restrain market growth.

The gastrointestinal disorders therapeutics market is set to experience strong generic competition during the forecast period, as several major branded drugs used in to treat gastrointestinal disorders are set to expire during 2011-2015, including Nexium (esomeprazole magnesium), Aciphex (rabeprazole sodium), Tysabri (natalizumab) and Humira (adalimumab). This will result in a decline in the Annual Cost of Treatment (ACT), from $291 in 2011 to $261 in 2018 at a negative Compound Annual Growth Rate (CAGR) of 1.5%, although the launch of novel biologics will stabilize this drop.

However the market is set to witness a steady growth from 2015 onwards due to the anticipated entry of innovative new drugs, as the industry shows strong R&D activity in IBS, constipation, Crohn's disease and UC with effective and novel drug molecules. There are approximately 269 ongoing clinical trials in the gastrointestinal disorders therapeutics market, with the main focus being on Crohn's disease and UC. 42% of all ongoing clinical trials are in Phase II and 22% are in the late stages (Phase III and NDA-filed). This robust pipeline increases the chance of getting new drugs to market and may represent better treatment options with fewer side effects.

The Irritable Bowel Syndrome (IBS) and constipation therapeutics markets were valued at $722m and $1.7 billion in 2011, and are expected to grow at CAGRs of 13.7% and 11.1% to $1.8 billion and $3.6 billion respectively in 2018. This high growth rate is attributed to the strong pipeline dominated by First-In-Class (FIC) molecules such as recently launched Linzess (linaclotide). Others include Plecanatide, Xifaxan (rifaximin), Asimadoline and Naloxegol (PEG-naloxol), most of which have demonstrated high safety and efficacy profiles in clinical trials. There is a significant level of unmet need associated with current treatment options for IBS and constipation, and if these new therapies can address them, they will be able to command a price premium, thus driving the market.

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

This report provides in-depth analysis of the major gastrointestinal diseases, comprising IBS, constipation, Crohn's disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). It gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 9
  • 1.2 List of Figures 12

2 Gastrointestinal Disorders Therapeutics Market - Introduction 15

  • 2.1 Overview 15

3 Global Gastrointestinal Disorders Therapeutics Market - Market Characterization 16

  • 3.1 Market Forecasts 16
    • 3.1.1 Branded and Generic Global Market Share 18
    • 3.1.2 Annual Cost of Treatment 19
    • 3.1.3 Treatment Usage Patterns 20
  • 3.2 Drivers and Restraints for the Global Gastrointestinal Disorders Therapeutics Market 22
    • 3.2.1 Market Drivers 22
    • 3.2.2 Market Restraints 23

4 Gastrointestinal Disorders Therapeutics Market - Geographical Landscape 24

  • 4.1 Revenue Analysis by Geography 24
  • 4.2 The US 24
    • 4.2.1 Revenue 24
    • 4.2.2 Annual Cost of Treatment 26
    • 4.2.3 Treatment Usage Patterns 27
  • 4.3 Top Five Countries of Europe 29
    • 4.3.1 Revenue 29
    • 4.3.2 Revenue by Country 30
    • 4.3.3 Annual Cost of Treatment 32
    • 4.3.4 Treatment Usage Patterns 33
  • 4.4 Japan 35
    • 4.4.1 Revenue 35
    • 4.4.2 Annual Cost of Treatment 37
    • 4.4.3 Treatment Usage Patterns 38
  • 4.5 Gastrointestinal Disorders Therapeutics Market India-Overview 40
    • 4.5.1 Epidemiology 40
    • 4.5.2 Clinical Trials 41
    • 4.5.3 Drivers and Restraints 41
  • 4.6 Gastrointestinal Disorders Therapeutics Market Australia-Overview 42
    • 4.6.1 Epidemiology 42
    • 4.6.2 Clinical Trials 43
    • 4.6.3 Drivers and Restraints 43
  • 4.7 Gastrointestinal Disorders Therapeutics Market China-Overview 44
    • 4.7.1 Epidemiology 44
    • 4.7.2 Clinical Trials 45
    • 4.7.3 Drivers and Restraints 45

5 Global Gastrointestinal Disorders Therapeutics Market - Therapeutic Landscape 46

  • 5.1 Global Irritable Bowel Syndrome Therapeutics Market Forecasts 46
    • 5.1.1 Introduction 46
    • 5.1.2 Treatment Flow Algorithm 47
    • 5.1.3 Revenue 48
    • 5.1.4 Revenue by Country 49
    • 5.1.5 Branded vs. Generic Market Share 51
    • 5.1.6 Annual Cost of Treatment 52
    • 5.1.7 Treatment Usage Patterns 53
  • 5.2 Drivers and Restraints for the Irritable Bowel Syndrome Therapeutics Market 55
    • 5.2.1 Drivers for the Irritable Bowel Syndrome Therapeutics Market 55
    • 5.2.2 Restraints for the Irritable Bowel Syndrome Therapeutics Market 55
  • 5.3 Global Constipation Therapeutics Market Forecasts 56
    • 5.3.1 Introduction 56
    • 5.3.2 Treatment Flow Algorithm 57
    • 5.3.3 Revenue 58
    • 5.3.4 Revenue Analysis by Country 59
    • 5.3.5 Branded vs. Generic Market Share 61
    • 5.3.6 Annual Cost of Treatment 62
    • 5.3.7 Treatment Usage Patterns 63
  • 5.4 Drivers and Restraints for the Constipation Therapeutics Market 65
    • 5.4.1 Drivers for Constipation Therapeutics Market 65
    • 5.4.2 Restraints for Constipation Therapeutics Market 65
  • 5.5 Global Crohn's Disease Therapeutics Market Forecasts 66
    • 5.5.1 Introduction 66
    • 5.5.2 Treatment Flow Algorithm 67
    • 5.5.3 Revenue 68
    • 5.5.4 Revenue by Country 69
    • 5.5.5 Branded vs. Generic Market Share 71
    • 5.5.6 Annual Cost of Treatment 72
    • 5.5.7 Treatment Usage Patterns 73
  • 5.6 Drivers and Restraints for the Crohn's Disease Therapeutics Market 75
    • 5.6.1 Drivers for the Crohn's Disease Therapeutics Market 75
    • 5.6.2 Restraints for the Crohn's Disease Therapeutics Market 75
  • 5.7 Global Ulcerative Colitis Therapeutics Market Forecasts 76
    • 5.7.1 Introduction 76
    • 5.7.2 Treatment Flow Algorithm 77
    • 5.7.3 Revenue 78
    • 5.7.4 Revenue by Country 79
    • 5.7.5 Branded vs. Generic Market Share 81
    • 5.7.6 Annual Cost of Treatment 82
    • 5.7.7 Treatment Usage Patterns 83
  • 5.8 Drivers and Restraints for the Ulcerative Colitis Therapeutics Market 85
    • 5.8.1 Drivers for the Ulcerative Colitis Therapeutics Market 85
    • 5.8.2 Restraints for the Ulcerative Colitis Therapeutics Market 85
  • 5.9 Global Gastroesophageal Reflux Disease Therapeutics Market Forecasts 86
    • 5.9.1 Introduction 86
    • 5.9.2 Treatment Flow Algorithm 87
    • 5.9.3 Revenue 89
    • 5.9.4 Revenue by Country 91
    • 5.9.5 Branded vs. Generic Market Share 93
    • 5.9.6 Annual Cost of Treatment 94
    • 5.9.7 Treatment Usage Patterns 95
  • 5.10 Drivers and Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 97
    • 5.10.1 Drivers for the Gastroesophageal Reflux Disease Therapeutics Market 97
    • 5.10.2 Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 97
  • 5.11 Global Peptic Ulcer Disease Therapeutics Market Forecasts 98
    • 5.11.1 Introduction 98
    • 5.11.2 Treatment Flow Algorithm 99
    • 5.11.3 Revenue 100
    • 5.11.4 Revenue Analysis by Country 102
    • 5.11.5 Generic vs. Branded Market Share 104
    • 5.11.6 Annual Cost of Treatment 105
    • 5.11.7 Treatment Usage Patterns 106
  • 5.12 Drivers and Restraints for the Peptic Ulcer Disease Therapeutics Market 108
    • 5.12.1 Drivers for Peptic Ulcer Disease Therapeutics Market 108
    • 5.12.2 Restraints for Peptic Ulcer Disease Therapeutics Market 108

6 Global Gastrointestinal Disorders Therapeutics Market - Pipeline Analysis 109

  • 6.1 Summary 109
  • 6.2 Research and Development Pipeline by Phase 109
  • 6.3 Research and Development Pipeline by Indication 110
  • 6.4 Irritable Bowel Syndrome: Research and Development Pipeline 111
    • 6.4.1 Pipeline by Phase 111
  • 6.5 Constipation: Research and Development Pipeline 112
    • 6.5.1 Research and Development Pipeline by Phase 112
  • 6.6 Crohn's Disease: Research and Development Pipeline 113
    • 6.6.1 Research and Development Pipeline by Phase 113
  • 6.7 Ulcerative Colitis: Research and Development Pipeline 114
    • 6.7.1 Research and Development Pipeline by Phase 114
  • 6.8 Gastroesophageal Reflux Disease: Research and Development Pipeline 115
    • 6.8.1 Research and Development Pipeline by Phase 115
  • 6.9 Peptic Ulcer Disease: Research and Development Pipeline 116
    • 6.9.1 Research and Development Pipeline by Phase 116
  • 6.10 Promising Pipeline Molecules 117
    • 6.10.1 Linzess (linaclotide) 118
    • 6.10.2 Xifaxan (rifaximin) 120
    • 6.10.3 Relistor (methylnaltrexone) 121
    • 6.10.4 Humira (adalimumab) 123
    • 6.10.5 Uceris (budesonide) 123
    • 6.10.6 Plecanatide 124
    • 6.10.7 Vedolizumab (MLN0002) 125
    • 6.10.8 Naloxegol (NKTR-118) 126
    • 6.10.9 Simponi (golimumab) 127
    • 6.10.10 Asimadoline 128
    • 6.10.11 Traficet-EN (GSK-1605786) 129
    • 6.10.12 Cobiprostone 130

7 Global Gastrointestinal Disorders Therapeutics Market - Competitive Landscape 131

  • 7.1 Market Share Analysis 131
  • 7.2 Profiles of Major Companies 132
    • 7.2.1 AstraZeneca 132
    • 7.2.2 Takeda Pharmaceutical Company 133
    • 7.2.3 Johnson & Johnson 135
    • 7.2.4 Eisai Co., Ltd. 136
    • 7.2.5 Abbott Laboratories 137
    • 7.2.6 Shire 138
    • 7.2.7 Salix Pharmaceuticals 139

8 Global Gastrointestinal Disorders Therapeutics Market - Strategic Consolidations 142

  • 8.1 Overview 142
  • 8.2 Mergers and Acquisitions 143
    • 8.2.1 Major Mergers and Acquisitions Deals 143
    • 8.2.2 Segmentation by Geography 146
    • 8.2.3 Segmentation by Deal Value 147
    • 8.2.4 Segmentation by Year 148
  • 8.3 Licensing Deals 149
    • 8.3.1 Major Licensing Deals 149
    • 8.3.2 Segmentation by Geography 152
    • 8.3.3 Segmentation by Deal Value 153
    • 8.3.4 Segmentation by Year 154
  • 8.4 Co-development/Co-marketing Deals 155
    • 8.4.1 Major Co-development/Co-marketing Deals 155
    • 8.4.2 Segmentation by Geography 158
    • 8.4.3 Segmentation by Deal Value 159
    • 8.4.4 Segmentation by Year 160

9 Gastrointestinal Disorders Therapeutics Market - Appendix 161

  • 9.1 Abbreviations 161
  • 9.2 Market Definitions 162
  • 9.3 Bibliography 162
  • 9.4 Research Methodology 166
    • 9.4.1 Secondary Research 166
    • 9.4.2 Primary Research 166
    • 9.4.3 Expert Panel Validation 167
    • 9.4.4 Section-wise Research Methodology 167
  • 9.5 Therapeutic Landscape 167
    • 9.5.2 Market Size by Geography 169
  • 9.6 Geographical Landscape 170
  • 9.7 Pipeline Analysis 170
  • 9.8 Competitive Landscape 170
  • 9.9 Strategic Consolidations 170
  • 9.10 Contact Us 170
  • 9.11 Disclaimer 171

List of Tables

  • Table 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004-2011 16
  • Table 2: Gastrointestinal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 16
  • Table 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011 19
  • Table 4: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018 19
  • Table 5: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2004-2011 20
  • Table 6: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2011-2018 21
  • Table 7: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004-2011 24
  • Table 8: Gastrointestinal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018 24
  • Table 9: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2011 26
  • Table 10: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2011-2018 26
  • Table 11: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2004-2011 27
  • Table 12: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2011-2018 28
  • Table 13: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 29
  • Table 14: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecast, ($bn), 2011-2018 29
  • Table 15: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2004-2011 30
  • Table 16: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts by Country ($bn), 2011-2018 31
  • Table 17: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004-2011 32
  • Table 18: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2011-2018 32
  • Table 19: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2004-2011 33
  • Table 20: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2011-2018 34
  • Table 21: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004-2011 35
  • Table 22: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2011-2018 35
  • Table 23: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2011 37
  • Table 24: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2011-2018 37
  • Table 25: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2004-2011 38
  • Table 26: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2011-2018 39
  • Table 27: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), India, 2011 40
  • Table 28: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, India, 2012 41
  • Table 29: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), Australia, 2011 42
  • Table 30: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, Australia, 2012 43
  • Table 31: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), China, 2011 44
  • Table 32: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, China, 2012 45
  • Table 33: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004-2011 48
  • Table 34: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 48
  • Table 35: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2004-2011 49
  • Table 36: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecast by Country ($m), 2011-2018 50
  • Table 37: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011 52
  • Table 38: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018 52
  • Table 39: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011 53
  • Table 40: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018 54
  • Table 41: Constipation Therapeutics Market, Global, Revenue ($m), 2004-2011 58
  • Table 42: Constipation Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 58
  • Table 43: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004-2011 59
  • Table 44: Constipation Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 60
  • Table 45: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011 62
  • Table 46: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018 62
  • Table 47: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011 63
  • Table 48: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018 64
  • Table 49: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2004-2011 68
  • Table 50: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 68
  • Table 51: Crohn's Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2011 69
  • Table 52: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 70
  • Table 53: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011 72
  • Table 54: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018 72
  • Table 55: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004-2011 73
  • Table 56: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2011-2018 74
  • Table 57: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004-2011 78
  • Table 58: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 78
  • Table 59: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004-2011 79
  • Table 60: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecast by Country ($m), 2011-2018 80
  • Table 61: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011 82
  • Table 62: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018 82
  • Table 63: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011 83
  • Table 64: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018 84
  • Table 65: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m), 2004-2011 89
  • Table 66: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 89
  • Table 67: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2011 91
  • Table 68: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 92
  • Table 69: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011 94
  • Table 70: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018 94
  • Table 71: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011 95
  • Table 72: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018 96
  • Table 73: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004-2011 100
  • Table 74: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 100
  • Table 75: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2011 102
  • Table 76: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018 103
  • Table 77: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011 105
  • Table 78: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018 105
  • Table 79: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011 106
  • Table 80: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018 107
  • Table 81: Gastrointestinal Disorders Therapeutics Market, Global, NDA-filed Molecules, 2012 117
  • Table 82: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase III Molecules, 2012 117
  • Table 83: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase II Molecules, 2012 117
  • Table 84: Gastrointestinal Disorders Therapeutics Market, Global, Major M&A Deals, 2010-Mid 2012 143
  • Table 85: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography, 2010-Mid-2012 146
  • Table 86: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2010-Mid-2012 147
  • Table 87: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010-Mid-2012 148
  • Table 88: Gastrointestinal Disorders Therapeutics Market, Global, Major Licensing Deals, 2010-Mid-2012 149
  • Table 89: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography, 2010-Mid-2012 152
  • Table 90: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value, 2010-Mid 2012 153
  • Table 91: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010-Mid-2012 154
  • Table 92: Gastrointestinal Disorders Therapeutics Market, Global, Major Co-development/Co-Marketing Deals, 2010-Mid-2012 155
  • Table 93: Gastrointestinal Disorders Therapeutics Market, Global, Co-development/Marketing Deals by Geography, 2010-Mid-2012 158
  • Table 94: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value, 2010-Mid-2012 159
  • Table 95: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010-Mid-2012 160

List of Figures

  • Figure 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004-2018 16
  • Figure 2: Gastrointestinal Disorders Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 18
  • Figure 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 19
  • Figure 4: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2004-2018 20
  • Figure 5: Gastrointestinal Disorders Therapeutics Market, Global, Market Drivers and Restraints 22
  • Figure 6: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004-2018 24
  • Figure 7: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018 26
  • Figure 8: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2004-2018 27
  • Figure 9: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018 29
  • Figure 10: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2004-2018 30
  • Figure 11: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004-2018 32
  • Figure 12: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2004-2018 33
  • Figure 13: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004-2018 35
  • Figure 14: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018 37
  • Figure 15: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2004-2018 38
  • Figure 16: Irritable Bowel Syndrome Therapeutics Market, Global, Breakdown of Irritable Bowel Syndrome Subtypes(%), 2012 46
  • Figure 17: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Flow Algorithm for Irritable Bowel Syndrome 47
  • Figure 18: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004-2018 48
  • Figure 19: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2004-2018 49
  • Figure 20: Irritable Bowel Syndrome Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 51
  • Figure 21: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 52
  • Figure 22: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018 53
  • Figure 23: Irritable Bowel Syndrome Therapeutics Market, Global, Market Drivers and Restraints 55
  • Figure 24: Constipation Therapeutics Market, Global, Treatment Flow Algorithm for Constipation 57
  • Figure 25: Constipation Therapeutics Market, Global, Revenue ($m), 2004-2018 58
  • Figure 26: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004-2018 59
  • Figure 27: Constipation Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 61
  • Figure 28: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 62
  • Figure 29: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018 63
  • Figure 30: Constipation Therapeutics Market, Global, Market Drivers and Restraints 65
  • Figure 31: Crohn's Disease Therapeutics Market, Global, Treatment Flow Algorithm for Crohn's Disease 67
  • Figure 32: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2004-2018 68
  • Figure 33: Crohn's Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2018 69
  • Figure 34: Crohn's Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 71
  • Figure 35: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 72
  • Figure 36: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004-2018 73
  • Figure 37: Crohn's Disease Therapeutics Market, Global, Market Drivers and Restraints 75
  • Figure 38: Ulcerative Colitis Therapeutics Market, Global, Treatment Flow Algorithm for Ulcerative Colitis 77
  • Figure 39: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004-2018 78
  • Figure 40: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004-2018 79
  • Figure 41: Ulcerative Colitis Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 81
  • Figure 42: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 82
  • Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018 83
  • Figure 44: Ulcerative Colitis Therapeutics Market, Global, Market Drivers and Restraints 85
  • Figure 45: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow Algorithm for Self and Primary-care Treatment 87
  • Figure 46: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow Algorithm for Secondary-care Treatment 88
  • Figure 47: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m), 2004-2018 89
  • Figure 48: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2018 91
  • Figure 49: Gastroesophageal Reflux Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 93
  • Figure 50: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 94
  • Figure 51: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018 95
  • Figure 52: Gastroesophageal Reflux Disease Therapeutics Market, Market Drivers and Restraints 97
  • Figure 53: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Flow Algorithm 99
  • Figure 54: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004-2018 100
  • Figure 55: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2018 102
  • Figure 56: Peptic Ulcer Disease Therapeutics Market, Global, Generic vs. Branded Market Share (%) 104
  • Figure 57: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 105
  • Figure 58: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018 106
  • Figure 59: Peptic Ulcer Disease Therapeutics Market, Market Drivers and Restraints 108
  • Figure 60: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Phase, (%), 2012 109
  • Figure 61: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Indication, (%), 2012 110
  • Figure 62: Gastrointestinal Disorders Therapeutics Market, Global, IBS Pipeline by Phase, (%), 2012 111
  • Figure 63: Gastrointestinal Disorders Therapeutics Market, Global, Constipation Pipeline by Phase, (%), 2012 112
  • Figure 64: Gastrointestinal Disorders Therapeutics Market, Global, Crohn's Disease Pipeline by Phase, (%), 2012 113
  • Figure 65: Gastrointestinal Disorders Therapeutics Market, Global, Ulcerative Colitis Pipeline by Phase, (%), 2012 114
  • Figure 66: Gastrointestinal Disorders Therapeutics Market, Global, GERD Pipeline by Phase, (%), 2012 115
  • Figure 67: Gastrointestinal Disorders Therapeutics Market, Global, Peptic Ulcer Disease Pipeline by Phase, (%), 2012 116
  • Figure 68: Gastrointestinal Disorders Therapeutics Market, Global, Market Share by Company, %, 2011 131
  • Figure 69: Gastrointestinal Disorders Therapeutics Market, AstraZeneca, SWOT Analysis 132
  • Figure 70: Gastrointestinal Disorders Therapeutics Market, Takeda Pharmaceutical Company, SWOT Analysis 134
  • Figure 71: Gastrointestinal Disorders Therapeutics Market, Johnson & Johnson, SWOT Analysis 135
  • Figure 72: Gastrointestinal Disorders Therapeutics Market, Eisai Company Limited, SWOT Analysis 136
  • Figure 73: Gastrointestinal Disorders Therapeutics Market, Abbott Laboratories, SWOT Analysis 137
  • Figure 74: Gastrointestinal Disorders Therapeutics Market, Shire, SWOT Analysis 138
  • Figure 75: Gastrointestinal Disorders Therapeutics Market, Salix Pharmaceuticals, SWOT Analysis 140
  • Figure 76: Gastrointestinal Disorders Therapeutics Market, Deals by Type, 2010-Mid-2012 142
  • Figure 77: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography, 2010-Mid-2012 146
  • Figure 78: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2010-Mid-2012 147
  • Figure 79: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010-Mid-2012 148
  • Figure 80: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography, 2010-Mid-2012 152
  • Figure 81: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m), 2010-Mid-2012 153
  • Figure 82: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010-Mid-2012 154
  • Figure 83: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by Geography, 2010-Mid-2012 158
  • Figure 84: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m), 2010-Mid-2012 159
  • Figure 85: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by Year, 2010-Mid 2012 160
  • Figure 86: GBI Research Market Forecasting Model 169
Back to Top